Impact of Antibody Cocktail Therapy Combined with Casirivimab and Imdevimab on Clinical Outcome for patients with COVID-19 in A Real-Life Setting: A Single Institute Analysis

BACKGROUND: Recent data from clinical trials suggest that antibody cocktail therapy, which combined casirivimab and imdevimab, is linked to the reduction of the risk of hospitalization or death among high-risk patients with COVID-19. However, it remains unclear how effective the therapy is in a real...

Descripción completa

Detalles Bibliográficos
Autores principales: Kakinoki, Yasutaka, Yamada, Kazuki, Tanino, Yoko, Suzuki, Keiko, Ichikawa, Takaya, Suzuki, Naoki, Asari, Go, Nakamura, Ai, Kukita, Shin, Uehara, Akito, Saito, Seisuke, Kuroda, Shohei, Sakagami, Hidemitsu, Nagashima, Yuuki, Takahashi, Kae, Suzuki, Satoshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8843326/
https://www.ncbi.nlm.nih.gov/pubmed/35176486
http://dx.doi.org/10.1016/j.ijid.2022.01.067

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8843326/
https://www.ncbi.nlm.nih.gov/pubmed/35176486
http://dx.doi.org/10.1016/j.ijid.2022.01.067

Ejemplares similares